The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | Russian |
| Julkaistu: |
«FIRMA «SILICEA» LLC
2021-04-01
|
| Sarja: | Российский кардиологический журнал |
| Aiheet: | |
| Linkit: | https://russjcardiol.elpub.ru/jour/article/view/4323 |